NCT06654726View on ClinicalTrials.gov

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 21, 2024

Primary Completion Date

December 5, 2024

Study Completion Date

March 18, 2025

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

aldafermin

aldafermin

DRUG

Placebo

placebo

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY

NCT06654726 - A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. | Biotech Hunter | Biotech Hunter